Nootropics are a brand new type of cognitive enhancing drug, they are not regulated i the US and most are still pending FDA approval. Nootropics also pose no notable side effects (unless stated otherwise) as long as proper dosage instructions are followed.
Dihexa is a relatively new drug that has been synthesized for the purpose of treating Alzheimer’s Disease. Developed by researchers from Washington State University, Dihexa has been shown to bolster cognitive function in lab rats with an Alzheimer-like mental disorder. It is extremely popular among the medical community thanks to its unique approach to the disease; whereas most Alzheimer’s drugs impede the progression of the disease, Dihexa repairs the damage in the synapse between neurons.
Researchers Harding and Wright worked tirelessly to . By 2012, they had found a way for their compound to cross the blood-brain barrier. Although the FDA has yet to approve Dihexa, Harding and Wright’s hard work has already been vindicated courtesy of the nootropic community’s enthusiasm for and support of the drug.
Dihexia, or Dihexa, as it is more commonly known, has been called a “neurogenic wonder-drug” by Nootropix.com. In their comprehensive review of the substance, the drug was said to be ten million times stronger than BDNF, one of the leading medications for new synapse formation.
The specific mechanisms of Dihexa are still nebulous at best and little information about the drug is available online or in medical journals. This much is clear: Harding and Wright discovered this wonder-drug’s properties quite by accident. In the course of their usual experimentation into ACE inhibitors and the like, they stumbled upon a sequence of angiotensin that didn’t induce the hypertensive effects of its predecessors. Further exploration found that said angiotensin (Angiotensin IV) pooled inside the hippocampus portion of the brain. This lead to the hypothesis that there was a correlation between Angiotensin IV and memory formation.
Armed with a pharmacological grant from the company behind such drugs as Cymbalta and Prozac, Harding and his team were able to develop a multitude of Angiotensin IV analogues for further testing. His hard work parlayed itself into miraculous findings; Ang-IV, as it is known in short form, was able to reverse all impairment across multiple cognitive models of decline.
Unfortunately for Harding and Co., funding was pulled when the above-mentioned company was plunged into scandal for failing to warn patients of the potential risks of birth defects when taking Prozac. Lawsuits followed and the project was shelved . Testing wouldn’t resume for some time.
In the early-Aughts, the project was picked up and dusted off. It was then that Harding narrowed in on the particular peptides requisite to the precognitive properties of a specific analogue in their experimentation. The analogue, known as Nle-Angiotensin-IV, was altered and a tripeptide sequence was concocted. Additional modification was undertaken and, after some time, they had the analogue now referred to as Dihexa (MM-201).
The dimerization process of Dihexa is behind the management of proteins which bind with DNA strands. The growth factor in its activated form yields increased HGF activity and diminishes dimerization. HGF activity, or Hepatocyte Growth Factor, stimulates DNA synthesis and builds up an uptake of hepatocytes, cells that are involved in protein synthesis. Dimerization is a macromolecular complex. HGF activity is responsible for synaptogenic and procognitive activities.
In addition to Alzheimer’s, Dihexa has been used to manage depression, improve general long and short-term memory, focus and learning. That said, its primary reputation is as a potent nootropic supplement for those afflicted with AD. It has also been considered as a prospective guard against aminoglycoside toxicity in hair cells. The outcome of this test found that Dihexa provided optimal protection against severe treatment with otoxin.
Note; dosage information is only for scientific reference purposes. SARMs Central, does not condone the human consumption or use of this substance outside of a controlled scientific environment (i.e. a lab).
Formal testing of Dihexa in human trials has yet to even begin, due to the lack of funding for such research, and anecdotal reports are varied. Users listed dosages everywhere from 8 to 45 mg per day and report a variety of benefits, from increased mental stamina to heightened articulation.
Users have reported increases in creative thinking, social intuition, and problem-solving skills. There has also been a fair deal of non-responders who haven’t felt anything at all.